200 related articles for article (PubMed ID: 22528335)
1. Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population.
Sivoňová MK; Dobrota D; Dušenka R; Waczulíková I; Slezák P; Matáková T; Mahmoodová S; Mištuna D; Kliment J
Mol Biol Rep; 2012 Aug; 39(8):7871-80. PubMed ID: 22528335
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
[TBL] [Abstract][Full Text] [Related]
3. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
dos Santos RM; de Jesus CM; Trindade Filho JC; Trindade JC; de Camargo JL; Rainho CA; Rogatto SR
DNA Cell Biol; 2008 Sep; 27(9):497-503. PubMed ID: 18491956
[TBL] [Abstract][Full Text] [Related]
4. Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer.
Tajtakova M; Pidanicova A; Valansky L; Lachvac L; Nagy V; Sivonova M; Dobrota D; Kliment J; Petrovicova J
Neoplasma; 2010; 57(2):118-22. PubMed ID: 20099974
[TBL] [Abstract][Full Text] [Related]
5. Relationship between CYP17 gene polymorphisms and risk of prostate cancer.
Song J; Tao ZH; Liu XY; Gong S; Gan L
Genet Mol Res; 2016 Feb; 15(1):15017866. PubMed ID: 26985923
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
7. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population.
Okugi H; Nakazato H; Matsui H; Ohtake N; Nakata S; Suzuki K
Cancer Detect Prev; 2006; 30(3):262-8. PubMed ID: 16859836
[TBL] [Abstract][Full Text] [Related]
8. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
[TBL] [Abstract][Full Text] [Related]
9. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
10. The association between estrogen receptor alpha polymorphisms and the risk of prostate cancer in Slovak population.
Jurečeková J; Sivoňová MK; Evinová A; Kliment J; Dobrota D
Mol Cell Biochem; 2013 Sep; 381(1-2):201-7. PubMed ID: 23737135
[TBL] [Abstract][Full Text] [Related]
11. Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
Hamada A; Danesi R; Price DK; Sissung T; Chau C; Venzon D; Sparreboom A; Dahut WL; Figg WD
Urology; 2007 Aug; 70(2):217-20. PubMed ID: 17826473
[TBL] [Abstract][Full Text] [Related]
12. Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer.
Chavan SV; Maitra A; Roy N; Chavan PR
Indian J Med Res; 2014 Mar; 139(3):371-8. PubMed ID: 24820830
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
14. Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement.
Schatzl G; Gsur A; Bernhofer G; Haidinger G; Hinteregger S; Vutuc C; Haitel A; Micksche M; Marberger M; Madersbacher S
Urology; 2001 Mar; 57(3):567-72. PubMed ID: 11248649
[TBL] [Abstract][Full Text] [Related]
15. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
[TBL] [Abstract][Full Text] [Related]
16. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
Tigli H; Yazici H; Dalay N
Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129
[TBL] [Abstract][Full Text] [Related]
17. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
Xu J; Meyers DA; Sterling DA; Zheng SL; Catalona WJ; Cramer SD; Bleecker ER; Ohar J
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):664-9. PubMed ID: 12101115
[TBL] [Abstract][Full Text] [Related]
18. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
19. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort.
Xue WM; Coetzee GA; Ross RK; Irvine R; Kolonel L; Henderson BE; Ingles SA
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):575-9. PubMed ID: 11401905
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population.
Wang LZ; Sato K; Tsuchiya N; Yu JG; Ohyama C; Satoh S; Habuchi T; Ogawa O; Kato T
Cancer Lett; 2003 Dec; 202(1):53-9. PubMed ID: 14643026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
